Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Intangibles (2020 - 2025)

10x Genomics (TXG) has disclosed Intangibles for 6 consecutive years, with $62.3 million as the latest value for Q4 2025.

  • Quarterly Intangibles rose 297.73% to $62.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $62.3 million through Dec 2025, up 297.73% year-over-year, with the annual reading at $62.3 million for FY2025, 297.73% up from the prior year.
  • Intangibles hit $62.3 million in Q4 2025 for 10x Genomics, down from $64.8 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $64.8 million in Q3 2025 to a low of $200000.0 in Q4 2023.
  • Historically, Intangibles has averaged $24.1 million across 5 years, with a median of $22.3 million in 2023.
  • Biggest five-year swings in Intangibles: crashed 99.13% in 2023 and later skyrocketed 7735.5% in 2024.
  • Year by year, Intangibles stood at $25.4 million in 2021, then dropped by 10.0% to $22.9 million in 2022, then plummeted by 99.13% to $200000.0 in 2023, then surged by 7735.5% to $15.7 million in 2024, then soared by 297.73% to $62.3 million in 2025.
  • Business Quant data shows Intangibles for TXG at $62.3 million in Q4 2025, $64.8 million in Q3 2025, and $14.7 million in Q2 2025.